GlobeNewswire by notified

Clinical ink Forms Strategic Alliance with Boston Clinical Research Institute

Share

Alliance Amplifies Clinical ink's Scientific Expertise to Support Improved Patient Outcomes

Horsham, PA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Today Clinical ink, a global life science technology company, announces an strategic alliance with The Boston Clinical Research Institute (BCRI), an Academic Research Organization (ARO) based in Boston, Massachusetts. The alliance will combine BCRI’s leadership in clinical strategy, therapeutic area expertise, and academic collaboration with Clinical ink’s expertise in eSource technology, including Direct Data Capture (DDC), electronic Clinical Outcomes Assessments (eCOA), and digital biomarkers.

BCRI provides scientific consultancy in study design, patient-centric modalities, endpoint selection, and complex data analysis by leveraging expert clinicians and key opinion leaders from premier medical institutions—with a goal to help advance health and quality of life around the world. To date, the institute has managed 450 studies which have enrolled over 160,000 patients, and has played a role in more than 50 FDA submissions.

"We are extremely pleased to announce this alliance," said Michael Gibson, MD, President and Chief Executive Officer of BCRI. “The path forward for global clinical trials will be forged via the expert design and planning of therapeutic thought leaders who will recommend the implementation of innovative and clinically-relevant eSource technology.”

Commenting on the alliance, Dr. Jonathan Goldman, MD, the Chief Executive Officer of Clinical ink, said, "We are delighted that Dr. Gibson and BCRI have aligned with Clinical ink. This relationship provides our trusted Sponsor and CRO partners access to a breadth of clinical and key opinion leader expertise in trial design, as well as clinical and digital endpoint selection across a full range of therapeutic areas.”

About Clinical Ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials.  

About Boston Clinical Research Institute

The Boston Clinical Research Institute is a non-profit academic research organization (ARO), based in Boston, but with experience in research that spans the world. Our team delivers insights, innovation, and leadership to develop creative solutions that reduce obstacles to implementation and enrollment of clinical trials. We collaborate with the world’s leading researchers from national and international institutions to design, implement, and complete clinical trials, and then develop programs to translate the results into clinical practice. Our entire team is fiercely committed to finding creative solutions and delivering timely research that helps advance health and quality of life around the world.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

NGS Group AB: NGS Group offentliggör utfall i riktad emission om 16,1 MSEK3.5.2024 18:00:00 CEST | Pressemelding

NGS Group AB:s (publ) (”NGS Group” eller ”Bolaget”) nyemission av aktier riktad till strategiska investerare om cirka 16,1 MSEK, före emissionskostnader (den ”Riktade Emissionen”) som beslutades av styrelsen den 29 februari 2024 och godkändes av den extra bolagsstämman den 26 mars 2024, har tecknats med totalt 4 962 577 aktier. Genom den Riktade Emissionen tillförs Bolaget cirka 16,1 MSEK, före avdrag för emissionskostnader. Utfall i den Riktade Emissionen Hugo Lewné och Nils Sjögren har tecknat och tilldelats totalt 4 962 577 aktier motsvarande cirka 16,1 MSEK i den Riktade Emissionen. Storleken på den Riktade Emissionen styrdes av teckningsgraden i den nyemission av aktier med företrädesrätt för befintliga aktieägare om ca 35,2 MSEK, före emissionskostnader (”Företrädesemissionen” och tillsammans med den Riktade Emissionen ”Emissionerna”) vari slutligt utfall offentliggjordes den 29 april 2024. Då Företrädesemissionen övertecknades innebär det att den Riktade Emissionens omfattning ä

Bulletin from BTS Group AB's Annual General Meeting3.5.2024 17:34:40 CEST | Press release

Stockholm May 3, 2024 The Annual General Meeting approved the proposed dividend to shareholders of SEK 5,70 per share, divided into two payment occasions of SEK 2,85 each. The record date for the first payment of SEK 2,85 was determined to Tuesday May 7, 2024 and for the second payment of SEK 2,85 was determined to Wednesday November 13, 2024. The first payment is expected to be made on Monday May 13, 2024 and the second payment is expected to be made on Monday November 18, 2024. The Annual General Meeting discharged the members of the Board of Directors and the CEO from liability for the financial year 2023 and approved the remuneration report for 2023 prepared by the Board of Directors. The Annual General Meeting approved the remuneration to board members to a total of SEK 1,735,000, of which SEK 525,000 to the Chairman and SEK 235,000 to each of the other board members, and SEK 60,000 to the Deputy Board member. A total fee of SEK 225,000 shall be paid for committee work. Mariana Bu

Kommuniké från BTS Group ABs årsstämma3.5.2024 17:34:40 CEST | Pressemelding

Stockholm 3 maj 2024 Årsstämman fastställde föreslagen utdelning till aktieägarna om 5,70 kronor per aktie, uppdelat på två utbetalningstillfällen om vardera 2,85 SEK. Som avstämningsdag för den första utbetalningen om 2,85 SEK fastställdes tisdagen den 7 maj 2024 och för den andra utbetalningen om 2,85 SEK fastställdes onsdagen den 13 november 2024. Den första utbetalningen beräknas ske måndagen den 13 maj 2024 och den andra utbetalningen beräknas ske måndagen den 18 november 2024. Årsstämman beviljade styrelseledamöterna och verkställande direktören ansvarsfrihet för verksamhetsåret 2023 samt godkände den av styrelsen upprättade ersättningsrapporten för 2023. Årsstämman fastställde arvodet till styrelseledamöter till totalt 1 735 000 kronor, varav 525 000 kronor till ordföranden och 235 000 kronor till respektive övrig styrelseledamot, samt 60 000 kronor till styrelsesuppleanten. För utskottsarbete skall ett totalt arvode om 225 000 kronor utgå. Mariana Burenstam Linder, Stefan Garde

Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer3.5.2024 17:32:16 CEST | Press release

Wistar’s Veglia lab identified how glioblastoma evades the immune system by inducing pro-tumor macrophages via a glucose based epigenetic modification. PHILADELPHIA, PA, May 03, 2024 (GLOBE NEWSWIRE) -- The Wistar Instituteassistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma — a serious and often fatal brain cancer — suppresses the immune system so that the tumor can grow unimpeded by the body’s defenses. The lab’s discovery was published in the paper, “Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma,” in the journal Immunity. “Our study shows that the cellular mechanisms of cancer’s self-preservation, when sufficiently understood, can be used against the disease very effectively,” said Dr. Veglia. “I look forward to future research on metabolism-driven mechanisms of immunosuppression in glioblastoma, and I’m hopeful for all that we will continue to learn about

HiddenA line styled icon from Orion Icon Library.Eye